What is the recommended management of nosocomial infections, including infection‑control measures and empiric antimicrobial therapy for pneumonia, catheter‑associated urinary tract infection, bloodstream infection, and Clostridioides difficile colitis?

Nosocomial Infection Management

For nosocomial infections, implement immediate multimodal infection control strategies including strict hand hygiene, catheter/line removal when possible, and initiate empiric antimicrobial therapy based on local resistance patterns and infection site, with mandatory de-escalation within 48-72 hours based on culture results.

Infection Control Measures

The foundation of nosocomial infection management requires multimodal strategies incorporating at least three core elements 1:

• Hand hygiene compliance - alcohol-based hand rub consumption monitoring
• Environmental controls - standardized catheter care protocols
• Audit and feedback systems - continuous surveillance of infection rates
• Education programs - multidisciplinary team training
• Bundles implementation - site-specific prevention protocols

Critical pitfall: Duration of catheterization is the single most important modifiable risk factor across all device-associated infections 2. Remove all unnecessary catheters and lines immediately.

Hospital-Acquired Pneumonia (HAP/VAP)

Diagnosis

Suspect pneumonia when patients have new/worsening pulmonary infiltrate PLUS any two of 3:

• Leukocyte count >10,000 or <4,000/µL
• Temperature >38.3°C
• Purulent respiratory secretions

Before initiating antibiotics: Obtain blood cultures and respiratory samples (sputum, endotracheal aspirate, or bronchoalveolar lavage) 3.

Empiric Therapy

For standard HAP/VAP (no MDRO risk factors):

• Piperacillin/tazobactam 4.5g IV q6h, OR
• Ceftazidime 2g IV q8h, OR
• Cefepime 2g IV q8-12h
• Duration: 7-8 days (not longer) 3

For MDRO risk (prior antibiotics, prolonged hospitalization, local resistance >10%):

• Ceftazidime/avibactam 2.5g IV q8h, OR
• Ceftolozane/tazobactam 3g IV q8h (for VAP specifically), OR
• Colistin-based combination therapy 4

Mandatory de-escalation: Narrow therapy at 48-72 hours based on cultures. Do not continue beyond 8 days unless inadequate source control 3.

Catheter-Associated Urinary Tract Infection (CAUTI)

Differentiation Critical

Do NOT treat asymptomatic bacteriuria (CA-ABU) - this is colonization, not infection 2.

Treat only symptomatic CAUTI with:

• Fever >38°C AND/OR
• Suprapubic tenderness AND/OR
• Costovertebral angle pain/tenderness AND/OR
• Altered mental status (elderly) with no other source

Management Approach

1. Replace or remove catheter before obtaining urine culture 2
2. Obtain urine culture from fresh catheter (not from existing catheter or collection bag)
3. Empiric therapy (5-7 days) 4:
   • For standard CAUTI: Fluoroquinolone (ciprofloxacin 400mg IV q8h) or ceftriaxone
   • For carbapenem-resistant Enterobacterales (CRE):
     • Ceftazidime/avibactam 2.5g IV q8h, OR
     • Aminoglycosides: Amikacin 15mg/kg IV daily or gentamicin 5-7mg/kg IV daily 4

Prevention is paramount: Avoid unnecessary catheterization, minimize duration, use aseptic insertion technique 2.

Central Line-Associated Bloodstream Infection (CLABSI)

Empiric Therapy

Remove or replace the central line when feasible 5.

For suspected CLABSI (10-14 days) 4:

• Gram-positive coverage: Vancomycin 15-20mg/kg IV q8-12h (target trough 15-20 mcg/mL)
• Gram-negative coverage:
  • Standard: Cefepime 2g IV q8h or piperacillin/tazobactam 4.5g IV q6h
  • MDRO risk: Ceftazidime/avibactam 2.5g IV q8h or meropenem/vaborbactam 4g IV q8h 4

For confirmed CRE bloodstream infection 4:

• First-line: Ceftazidime/avibactam 2.5g IV q8h (7-14 days)
• Alternative: Meropenem/vaborbactam 4g IV q8h
• If resistant to above: Colistin 5mg CBA/kg IV loading, then 2.5mg CBA × (1.5 × CrCl + 30) IV q12h PLUS tigecycline 100mg IV load, then 50mg IV q12h

Clostridioides difficile Infection (CDI)

Treatment Algorithm

Initial episode, non-severe:

• Vancomycin 125mg PO four times daily for 10 days, OR
• Fidaxomicin 200mg PO twice daily for 10 days 6

Initial episode, severe (WBC >15,000 or Cr >1.5× baseline):

• Vancomycin 125mg PO four times daily for 10 days
• Consider adding IV metronidazole 500mg q8h if ileus present 6

Fulminant CDI (hypotension, shock, ileus, megacolon):

• Vancomycin 500mg PO/NG four times daily PLUS metronidazole 500mg IV q8h
• Surgical consultation for possible colectomy
• Consider vancomycin retention enema if ileus

First recurrence:

• Vancomycin 125mg PO four times daily for 10 days, OR
• Fidaxomicin 200mg PO twice daily for 10 days (preferred) 6

Second or subsequent recurrence:

• Fidaxomicin extended/pulsed regimen, OR
• Vancomycin taper and pulse, OR
• Bezlotoxumab (monoclonal antibody) 10mg/kg IV single dose with antibiotics, OR
• Fecal microbiota transplantation 6

Critical: Stop all unnecessary antibiotics immediately. Do NOT use metronidazole as first-line therapy 6.

Key Principles Across All Nosocomial Infections

Microbiological sampling before antibiotics: Blood cultures (2 sets), site-specific cultures 3, 7

Know your local antibiogram: Empiric therapy must reflect institutional resistance patterns 7

Strict de-escalation protocol: Narrow spectrum at 48-72 hours based on cultures and clinical response 3

Source control is non-negotiable: Remove devices, drain abscesses, debride infected tissue 2

Combination therapy indications 4:

• Septic shock at presentation
• High risk of MDRO infection (prior MDRO, recent broad-spectrum antibiotics, ICU stay >5 days)
• Documented difficult-to-treat resistant organisms

Avoid prolonged courses: 5-7 days for CAUTI/intra-abdominal infections, 7-8 days for pneumonia, 10-14 days for bloodstream infections unless inadequate source control 4, 3